MedTrace Logo

Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

NCT05259527 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-05-14

No results posted yet for this study

Summary

This is a two-arm randomized clinical trial in which 80 participants with Vitamin D deficiency and scheduled to begin taxane-based chemotherapy will be randomized to either: 1) prescribed vitamin D replacement or 2) standard of care.

Conditions

  • Neuropathic Pain

Interventions

DIETARY_SUPPLEMENT

Cholecalciferol Capsules

Vitamin D3 5,000IU by mouth daily

DRUG

Ergocalciferol Capsules

Vitamin D2 50,000IU by mouth once weekly for 8 weeks then once per month thereafter.

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Susan Hong, MD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-19
Primary Completion
2030-03-31
Completion
2030-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259527 on ClinicalTrials.gov